Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

2.140 -0.040 (-1.83%)

Official Closing Price Updated: 8:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today ↗

December 29, 2021

Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around?

Via InvestorPlace

Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors

December 29, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

38 Stocks Moving In Tuesday's Mid-Day Session ↗

December 21, 2021

Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining...

Via Benzinga

55 Biggest Movers From Yesterday ↗

December 22, 2021

Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

December 21, 2021

Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

26 Stocks Moving in Tuesday's Pre-Market Session ↗

December 21, 2021

Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains...

Via Benzinga

65 Biggest Movers From Yesterday ↗

December 21, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher ↗

December 20, 2021

Toward the end of trading Monday, the Dow traded down 1.42% to 34,862.49 while the NASDAQ fell 1.38% to 14,960.51. The S&P also fell, dropping 1.34% to 4,558.87. The U.S. has...

Via Benzinga

Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient ↗

December 20, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson...

Via Benzinga

Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump ↗

December 20, 2021

Midway through trading Monday, the Dow traded down 1.78% to 34,735.33 while the NASDAQ fell 1.43% to 14,952.69. The S&P also fell, dropping 1.59% to 4,547.26. The U.S. has the...

Via Benzinga

RKT Stock: 15 Things to Know as Rocket Moves Beyond Mortgages With Truebill Deal ↗

December 20, 2021

Rocket Companies (RKT) stock is on the move Monday following news of a $1.275 billion acquisition deal with Truebill.

Via InvestorPlace

CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher Today ↗

December 20, 2021

Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer.

Via InvestorPlace

38 Stocks Moving In Monday's Mid-Day Session ↗

December 20, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF...

Via Benzinga

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

December 20, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Piclidenoson Takes On Otezla, a $13 Billion Psoriasis Drug ↗

December 14, 2021

Photo by Hal Gatewood on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022 ↗

December 07, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week...

Via Benzinga

Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022

December 07, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates ↗

November 26, 2021

Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX:C...

Via Benzinga

Earnings Scheduled For November 26, 2021 ↗

November 26, 2021

Companies Reporting Before The Bell Pinduoduo Inc. (NASDAQ:PDD) is expected to report quarterly earnings at $0.02 per share on revenue of $4.16 billion. BlueCity Holdings Limited...

Via Benzinga

Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021

November 24, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite's Kickstarts Piclidenoson Study For Canine Osteoarthritis ↗

November 23, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has commenced a safety and efficacy study of Piclidenoson to treat osteoarthritis in dogs. Safety results are expected in...

Via Benzinga

Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis

November 23, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference

November 12, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference

November 01, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico

October 28, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit

October 26, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal ↗

October 21, 2021

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule...

Via Benzinga

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal

October 21, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Hope on the Horizon for Liver Cancer Patients as This Company's Namodenoson Drug Starts Pivotal Phase III Global Trial ↗

October 08, 2021

Photo by National Cancer Institute on Unsplash Liver cancer is a growing global health concern. Apart from the financial burden it places on patients and economies, the American...

Via Benzinga

Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

October 05, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.